[go: up one dir, main page]

WO2010023340A3 - Novel biomarker as therapeutic target in lung cancer - Google Patents

Novel biomarker as therapeutic target in lung cancer Download PDF

Info

Publication number
WO2010023340A3
WO2010023340A3 PCT/ES2009/070347 ES2009070347W WO2010023340A3 WO 2010023340 A3 WO2010023340 A3 WO 2010023340A3 ES 2009070347 W ES2009070347 W ES 2009070347W WO 2010023340 A3 WO2010023340 A3 WO 2010023340A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
lung
rho
adenocarcinoma
copies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2009/070347
Other languages
Spanish (es)
French (fr)
Other versions
WO2010023340A2 (en
Inventor
Fernando Lecanda Cordero
Diego Luis-Ravelo Salazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of WO2010023340A2 publication Critical patent/WO2010023340A2/en
Publication of WO2010023340A3 publication Critical patent/WO2010023340A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for prognosis of the progression of the disease of a subject suffering from adenocarcinoma of the lung, which comprises either measuring expression of the Rho B gene or measuring the number of copies of the Rho B gene in a sample taken from said subject suffering from adenocarcinoma of the lung, characterized in that detection of the overexpression or increase in the number of copies of the Rho B gene as compared with expression or the number of copies of same gene in a control sample is indicative of the risk of metastasis or reappearance or recurrence of neoplastic activity. The present invention further provides screening methods for drugs that are active against adenocarcinoma of the lung with a view to determining the efficacy of a therapeutic treatment model in a subject suffering from adenocarcinoma of the lung and also drugs that inhibit overexpression of the Rho B gene, for use as a drug or for use in the treatment of non-small-cell lung cancers (NSCLC).
PCT/ES2009/070347 2008-08-28 2009-08-19 Novel biomarker as therapeutic target in lung cancer Ceased WO2010023340A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802503A ES2339524B1 (en) 2008-08-28 2008-08-28 NEW BIOMARCATOR AS A THERAPEUTIC DIANA IN CANCER DE PULMON.
ESP200802503 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010023340A2 WO2010023340A2 (en) 2010-03-04
WO2010023340A3 true WO2010023340A3 (en) 2010-05-20

Family

ID=41396098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2009/070347 Ceased WO2010023340A2 (en) 2008-08-28 2009-08-19 Novel biomarker as therapeutic target in lung cancer

Country Status (2)

Country Link
ES (1) ES2339524B1 (en)
WO (1) WO2010023340A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016809A1 (en) * 1998-09-18 2000-03-30 Isis Pharmaceuticals, Inc. ANTISENSE MODULATION OF RhoB EXPRESSION
WO2004024165A1 (en) * 2002-09-09 2004-03-25 Novartis Ag Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
US20060287237A1 (en) * 2000-06-16 2006-12-21 Sebti Said M RhoB as a suppressor of cancer cell growth, cell transformation, and metastasis
US20070059726A1 (en) * 2005-04-18 2007-03-15 Xiaohong Cao Differential transcript expression
WO2008031910A2 (en) * 2006-09-15 2008-03-20 Proyecto De Biomedicina Cima, S.L. Experimental models for non-microcytic lung cancer metastasis to bone
WO2008072777A2 (en) * 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642341B1 (en) * 1992-05-13 2000-07-19 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy
US20080167532A1 (en) * 2006-10-13 2008-07-10 Mayo Foundation For Medical Education And Research Assessing cancer treatment responsiveness

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016809A1 (en) * 1998-09-18 2000-03-30 Isis Pharmaceuticals, Inc. ANTISENSE MODULATION OF RhoB EXPRESSION
US20060287237A1 (en) * 2000-06-16 2006-12-21 Sebti Said M RhoB as a suppressor of cancer cell growth, cell transformation, and metastasis
WO2004024165A1 (en) * 2002-09-09 2004-03-25 Novartis Ag Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
US20070059726A1 (en) * 2005-04-18 2007-03-15 Xiaohong Cao Differential transcript expression
WO2008031910A2 (en) * 2006-09-15 2008-03-20 Proyecto De Biomedicina Cima, S.L. Experimental models for non-microcytic lung cancer metastasis to bone
WO2008072777A2 (en) * 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAZIÃRES JULIEN ET AL: "Epigenetic regulation of RhoB loss of expression in lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 30 November 2007 (2007-11-30), pages 220, XP021034508, ISSN: 1471-2407 *
MAZIERES JULIEN ET AL: "Loss of RhoB expression in human lung cancer progression.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 APR 2004, vol. 10, no. 8, 15 April 2004 (2004-04-15), pages 2742 - 2750, XP002561053, ISSN: 1078-0432 *
SATO NAOHITO ET AL: "RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 FEB 2007, vol. 120, no. 3, 1 February 2007 (2007-02-01), pages 543 - 551, XP002561054, ISSN: 0020-7136 *

Also Published As

Publication number Publication date
ES2339524B1 (en) 2011-03-22
ES2339524A1 (en) 2010-05-20
WO2010023340A2 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
Imaoka et al. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer
Luo et al. Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression
Yu et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1
Wang et al. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27
Hu et al. USP22 promotes tumor progression and induces epithelial–mesenchymal transition in lung adenocarcinoma
Yoo et al. MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer
WO2012103250A3 (en) Colon cancer gene expression signatures and methods of use
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
Shen et al. LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer
MX339340B (en) Methods for predicting and improving the survival of gastric cancer patients.
Wang et al. Expression of Rab1A is upregulated in human lung cancer and associated with tumor size and T stage
Zhang et al. Overexpression of HOTTIP promotes proliferation and drug resistance of lung adenocarcinoma by regulating AKT signaling pathway.
US20210054374A1 (en) Antitumor compounds and tumor diagnosis
Jo et al. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
Loeffler-Ragg et al. Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines
Liu et al. CEP131 indicates poor prognosis and promotes cell proliferation and migration in hepatocellular carcinoma
Chen et al. MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L
WO2017217807A3 (en) Biomarker comprising nckap1 as effective ingredient for diagnosing colorectal cancer or for predicting metastasis and prognosis of colorectal cancer
Edfeldt et al. A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesis
Yang et al. RETRACTED ARTICLE: Long Noncoding RNA KCNMB2-AS1 Increases ROCK1 Expression by Sponging microRNA-374a-3p to Facilitate the Progression of Non–Small-Cell Lung Cancer
Zhao et al. Identification of a potential tumor suppressor gene, UBL3, in non-small cell lung cancer
Liu et al. RETRACTED ARTICLE: MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2
JP2016506412A5 (en)
Kerkentzes et al. Hidden treasures in “ancient” microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue
Kumar et al. Expression and clinical significance of COMPASS family of histone methyltransferases in clear cell renal cell carcinoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784140

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01.08.2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09784140

Country of ref document: EP

Kind code of ref document: A2